The U.S. Food and Drug Administration (FDA) has issued a Public Health Alert for <"http://www.yourlawyer.com/practice_areas/defective_drugs">Que She Weight Loss Capsules because they contain potentially harmful ingredients.
Que She is marketed as an herbal weight loss supplement and contains active pharmaceutical ingredients not listed on the product label that could harm consumers, especially those with cardiovascular conditions. People who have purchased Que She should stop taking the product immediately and consult a health care professional, the FDA said.
Que She, advertised as â€œSlimming Factor Capsuleâ€ and as â€œan all-natural blend of Chinese herbs,â€ has been widely distributed on Internet sites such as the Bouncing Bear Botanicals Website, and at retail outlets, including Sacred Journey in Lawrence, Kansas.
An FDA analysis of Que She found that it contains:
â€¢ Fenfluramine: A stimulant drug withdrawn from the U.S. market in 1997 after studies demonstrated it caused serious heart valve damage.
â€¢ Propranolol: A prescription beta blocker drug that can pose a risk to people with bronchial asthma and certain heart conditions.
â€¢ Sibutramine: A controlled substance and prescription weight loss drug that was the subject of a recent study whose preliminary findings showed an association between sibutramine use and increased risk of heart attack and stroke in patients with a history of heart disease.
â€¢ Ephedrine: A stimulant drug legally marketed over-the-counter for the temporary relief of asthma, but that can pose a risk to people with certain cardiovascular conditions.
These active pharmaceutical ingredients also may interact with other medications and result in a serious adverse event.
Consumers and health care professionals are encouraged to report adverse events related to the use of Que She to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program: Online at www.fda.gov/MedWatch/report.htm; by phone at 800-FDA-1088 (800-332-1088); or, by returning FDA form 3500, available on the MedWatch “Download Forms” page by mail to the address on the pre-addressed form or by fax at 800-FDA-0178.